JPRN-UMIN000015917已完成2 期
Second line chemotherapy using gemcitabine and docetaxel for soft tissue sarcoma - Second line chemotherapy using gemcitabine and docetaxel for soft tissue sarcoma
Gifu University school of medicine0 个研究点目标入组 0 人开始时间: 2014年12月12日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
o participant.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •patient who doesn't show his/her assent patient considered to be not suitable for participating this trial
研究者
相似试验
进行中（未招募）
2 期
Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapyOsteosarcomaPulmonary MetastasesApatinibNCT03742193Ruijin Hospital43
已完成
2 期
Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's DiseaseHodgkin DiseaseHodgkin's LymphomaLymphomaNCT00388349Stanford University146
已完成
1 期
eoadjuvant chemotherpy with gemcitabine and oral S-1for pancreatic cancerresectable pancreatic cancerJPRN-UMIN000011064Department of Gastroenterologic Surgery, Kanazawa University18
招募中
不适用
Gemcitabine en radiotherapie in combinatie met panitumumab bij patiënten met niet uitgezaaide, inoperabele alvleesklierkanker.Pancreatic cancerPancreas cancerAlvleesklierkankerPancreaskankerNL-OMON25995Prof. dr. H.M.W. Verheul, M.D., Ph.D.Head Department of Medical OncologyVU University Medical CenterDe Boelelaan 11171081 HV AmsterdamPhone: +31-20-4444321/300Fax: + 31-20-4444079Email: h.verheul@vumc.nl63
已完成
不适用
eoadjuvant combined chemotherapy with gemcitabine, cisplatin and zoledronic acid against muscle invasive bladder cancerbladder cancerJPRN-UMIN000003146Department of Urology, Graduate School of Biomedical Sciences Hiroshima University30